about
Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines AgencySharing clinical trial data on patient level: opportunities and challengesSystematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditionsMethods for identification and confirmation of targeted subgroups in clinical trials: A systematic reviewOptimizing Trial Designs for Targeted Therapies"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?False discovery rate control in two-stage designs.Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov.Cross-platform comparison of microarray data using order restricted inference.Effect of intensive care after cardiac arrest on patient outcome: a database analysisSkateboarding injuries in Vienna: location, frequency, and severity.Bridging the gap: a review of dose investigations in paediatric investigation plansMorphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial.Sample Size Reassessment and Hypothesis Testing in Adaptive Survival TrialsTesting and estimation in flexible group sequential designs with adaptive treatment selection.Connections between permutation and t-tests: relevance to adaptive methods.Unplanned adaptations before breaking the blindModeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claimsSimultaneous confidence intervals that are compatible with closed testing in adaptive designsDecision-theoretic designs for small trials and pilot studies: A reviewAdaptive designs for confirmatory clinical trials.Impact of dental implant length on early failure rates: a meta-analysis of observational studies.Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)Determination of the optimal sample size for a clinical trial accounting for the population size.Adaptive graph-based multiple testing procedures.Sample size reassessment for a two-stage design controlling the false discovery rate.Weekends affect mortality risk and chance of discharge in critically ill patients: a retrospective study in the Austrian registry for intensive care.Estimation after blinded sample size reassessment.Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery.Post hoc power estimation in large-scale multiple testing problems.Evidence, eminence and extrapolation.Fallback tests for co-primary endpoints.Adaptive designs for subpopulation analysis optimizing utility functions.Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests.Multi-arm group sequential designs with a simultaneous stopping rule.Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.Physiotherapy-based rehabilitation following disc herniation operation: results of a randomized clinical trial.
P50
Q26824359-66B5D7B3-070D-467B-B906-45D0AE754B47Q26852063-6A581E2C-645D-40E1-BAB3-60A8DE447C0DQ28075766-577A0A98-2584-4A86-9034-CFAC2ACB06C9Q28086970-798BC6B7-1BB6-46B9-BB51-76937767992CQ28554393-4E08A0C8-DBCD-46E9-8F70-6DAF4D1687A4Q28595570-CADF92D9-DAB3-4382-A5B9-334B07861E9FQ30528299-43F922FD-6F7D-42AB-AAD4-A7660A37165DQ31169838-9DC24576-8A43-4A4B-8DBD-0589871B657BQ33819481-7610052D-4AEC-4BA6-BCD5-7F90AB1D3C69Q33821416-24E8F62C-1F22-490D-B81C-9456D4284E6BQ34127994-152F7040-E15E-4A4E-B349-4E6E364AA805Q34554486-5530B05D-0D9A-4C1F-BA0C-C3A8AE8DFB4FQ34658201-47C005A3-D5C1-4399-BC9D-2882E4DCF5F7Q35919624-C4790E8A-E1E2-4DBD-9EA4-FDC6A4DB9E8AQ36327917-4B7E95AB-B8F2-489D-B658-A386AD8E26D8Q36379731-C45064DC-FC95-4CAC-8D85-AD8904C35C29Q36621801-0D6EA2C7-20D7-4113-8834-49085109A334Q36693749-D0D2060D-651F-4750-A026-95FAD7DB5303Q36726422-A875A981-483B-40FE-BA1B-AB3F2608F5AAQ36925422-DA8A5E58-3595-4DE5-B32A-7676773BA7DFQ37389417-A5ED7B85-3BB7-46B0-9A1A-F746233A3B3CQ37896677-F6BF0BD9-DCC8-47FD-A5C5-DA4E0B473CBBQ38196390-34DDEF92-6D19-4C58-8C0C-110CA1FDFE26Q38672541-F68D3592-D59A-4DA4-AC0F-BA18982D352BQ38866634-F549CE18-6162-4E54-BC51-BEA93FB7B239Q38963322-26ED610B-E0F9-4966-8B33-D91A83DC478DQ38963341-01E84E54-2FD6-4C73-BDD1-ED26690F231FQ39090408-33F3D941-A442-4F17-BC04-0EB770CA5C47Q39327135-D937196A-6DDF-486B-A682-48310F9B5D51Q39608346-986D24F3-C820-45E2-B1AE-68DB3C3DD450Q40180557-FE12CB8D-879F-4273-A19F-CCB9F56C7A19Q40203376-A7E34B51-C35B-4745-BFC2-79FBFB605B59Q41422873-1A171319-BCCE-4944-A00B-36EE9BE062ECQ41477325-F08D1EEB-145F-4D8C-AB22-678F1FE8523DQ41498396-CD85A495-9B02-4432-B18A-A8E644CA7787Q42250318-18A2AA11-88B7-464A-B48D-1AAF5226593EQ42321286-D1422558-2B4E-4AB1-A17B-FC7AC1DF2DB8Q42352281-1919015C-E0A2-4ACE-96A5-5AB66E3F543EQ42485983-CF140D95-B518-4EAD-A330-CF8CEA85EB97Q42630319-8EA01FFE-BBB7-4424-87AE-355EF063762C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin Posch
@ast
Martin Posch
@en
Martin Posch
@es
Martin Posch
@nl
Martin Posch
@sl
type
label
Martin Posch
@ast
Martin Posch
@en
Martin Posch
@es
Martin Posch
@nl
Martin Posch
@sl
prefLabel
Martin Posch
@ast
Martin Posch
@en
Martin Posch
@es
Martin Posch
@nl
Martin Posch
@sl
P1053
C-7907-2009
P106
P1153
7007119138
P21
P31
P3829
P496
0000-0001-8499-8573